Büşra Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Büşra Tan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Izem Olcay Sahin
Erciyes Universitesi
3 shared publications - Munis Dundar
Department of Medical Genetics , School of Medicine , Erciyes University , Kayseri , Türkiye
3 shared publications - Emine Karatas
Department of Medical Genetics, Faculty of Medicine, Erciyes University, Kayseri, Turkiye
2 shared publications - Hüseyin Per
Department of Pediatrics, Division of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
2 shared publications - Yusuf Ozkul
Department of Medical Genetics, Faculty of Medicine, Erciyes University, Kayseri, Turkiye
2 shared publications - Abdulbaki Yildirim
Department of Medical Genetics, School of Medicine, Erciyes University, Kayseri, Turkey
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (10) , 1070
The Clinical and Phenotypic Significance of Sub-Threshold JAK2 V617F Signals in Patients Classified as JAK2 V617F-Negative
Background: This study investigates the relationship between clinical and hematological parameters and sub-threshold positive findings in cases with suspected hematological malignancies subjected to Janus Kinase 2 (JAK2) V617F qPCR testing. Methods: Adult patients referred to the Medical Genetics Clinic from the Erciyes University Faculty of Medicine Hematology Department between 2022 and 2024 for JAK2 V617F analysis due to suspected hematological malignancy were evaluated in this retrospective, cross-sectional study. Registered data from 2394 patients were analyzed, and 173 cases with a JAK2 V617F allele burden below 0.1% but above the negative control value were included in the study. SPSS version 25.0 software was used for statistical analysis. Results: More than half of the patients (56.6%) had no definitive hematological diagnosis at initial testing, while 28.9% developed a hematological disorder during follow-up, including overt MPN in 13.3%. Significant differences across VAF groups were observed for leukocytosis (p = 0.004), neutrophilia (p = 0.030), and monocytosis (p = 0.024), with the highest frequencies in Group 3 (0.041–0.099%). ROC analyses identified closely clustered optimal cut-offs around 0.027–0.029%, whereas no independent predictor of higher sub-threshold allele burden emerged in multivariate analysis (p > 0.05). Conclusions: Even sub-threshold levels of the JAK2 V617F mutation may exhibit specific clinical manifestations and may be associated with constitutional symptoms and leukocytosis in particular. The study findings also showed a lower awareness of the JAK2 test in clinical practice, and that it is significantly employed in off-label cases. In order to accurately interpret low-allele-burden results, molecular findings must be evaluated in conjunction with hematological parameters and appropriate clinical indications. The findings underscore the importance of applying the JAK2 V617F PCR test selectively and based on clinical suspicion.
- 16 October 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (10) , 1070
Open AccessThe Clinical and Phenotypic Significance of Sub-Threshold JAK2 V617F Signals in Patients Classified as JAK2 V617F-Negative
Background: This study investigates the relationship between clinical and hematological parameters and sub-threshold positive findings in cases with suspected hematological malignancies subjected to Janus Kinase 2 (JAK2) V617F qPCR testing. Methods: Adult patients referred to the Medical Genetics Clinic from the Erciyes University Faculty of Medicine Hematology Department between 2022 and 2024 for JAK2 V617F analysis due to suspected hematological malignancy were evaluated in this retrospective, cross-sectional study. Registered data from 2394 patients were analyzed, and 173 cases with a JAK2 V617F allele burden below 0.1% but above the negative control value were included in the study. SPSS version 25.0 software was used for statistical analysis. Results: More than half of the patients (56.6%) had no definitive hematological diagnosis at initial testing, while 28.9% developed a hematological disorder during follow-up, including overt MPN in 13.3%. Significant differences across VAF groups were observed for leukocytosis (p = 0.004), neutrophilia (p = 0.030), and monocytosis (p = 0.024), with the highest frequencies in Group 3 (0.041–0.099%). ROC analyses identified closely clustered optimal cut-offs around 0.027–0.029%, whereas no independent predictor of higher sub-threshold allele burden emerged in multivariate analysis (p > 0.05). Conclusions: Even sub-threshold levels of the JAK2 V617F mutation may exhibit specific clinical manifestations and may be associated with constitutional symptoms and leukocytosis in particular. The study findings also showed a lower awareness of the JAK2 test in clinical practice, and that it is significantly employed in off-label cases. In order to accurately interpret low-allele-burden results, molecular findings must be evaluated in conjunction with hematological parameters and appropriate clinical indications. The findings underscore the importance of applying the JAK2 V617F PCR test selectively and based on clinical suspicion.
- Open Access
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (4) , 880
Corrigendum to “A retrospective study on the clinical and molecular outcomes of calpainopathy in a Turkish patient cohort” [Turkish Journal of Medical Sciences 54 (1) 2024 86-98 ]
This corrigendum is written to correct an error in our previous publication. The term “LGMDD4” was incorrectly spelled as “LGMDD1” throughout the article. The correct term should be “LGMDD4”. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. Link to the original article: https://journals.tubitak.gov.tr/medical/vol54/iss1/11/
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (4) , 880
Open AccessCorrigendum to “A retrospective study on the clinical and molecular outcomes of calpainopathy in a Turkish patient cohort” [Turkish Journal of Medical Sciences 54 (1) 2024 86-98 ]
This corrigendum is written to correct an error in our previous publication. The term “LGMDD4” was incorrectly spelled as “LGMDD1” throughout the article. The correct term should be “LGMDD4”. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. Link to the original article: https://journals.tubitak.gov.tr/medical/vol54/iss1/11/
- Open Access
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (1) , 86-98
A retrospective study on the clinical and molecular outcomes of calpainopathy in a Turkish patient cohort
Calpainopathy, also known as limb-girdle muscular dystrophy recessive type 1, is a progressive muscle disorder that impacts the muscles around the hips and shoulders. The disease is caused by defects in the CAPN3 gene and can be inherited in both recessive and dominant forms. In this retrospective study, we aimed to evaluate the clinical and molecular results of our patients with calpainopathy and to examine the CAPN3 variants in Turkish and global populations.Materials and methods: Molecular analyses were performed using the next-generation sequencing (NGS) method. CAPN3 variants were identified through the examination of various databases.Results: In this retrospective study, the cohort consisted of seven patients exhibiting the CAPN3 (NM_000070.3) mutation and a phenotype compatible with calpainopathy at a single center in Türkiye. All patients displayed high CK levels and muscle weakness. We report a novel missense c.2437G>A variant that causes the autosomal dominant form of calpainopathy. Interestingly, the muscle biopsy report for the patient with the novel mutation indicated sarcoglycan deficiency. Molecular findings for the remaining individuals in the cohort included a compound heterozygous variant (frameshift and missense), one homozygous nonsense, one homozygous intronic deletion, and three homozygous missense variants. The most common variant in the Turkish population was c.550del. In both populations, pathogenic variants were most frequently located in exon 21, according to exon length. Variants were stochastically distributed based on consequences in CAPN3 domains.Conclusion: Therefore, the NGS method proves highly effective in diagnosing rare diseases characterized by clinical heterogeneity. Assessing variants based on ethnicity holds significance in the development of precise therapies.
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (1) , 86-98
Open AccessA retrospective study on the clinical and molecular outcomes of calpainopathy in a Turkish patient cohort
Calpainopathy, also known as limb-girdle muscular dystrophy recessive type 1, is a progressive muscle disorder that impacts the muscles around the hips and shoulders. The disease is caused by defects in the CAPN3 gene and can be inherited in both recessive and dominant forms. In this retrospective study, we aimed to evaluate the clinical and molecular results of our patients with calpainopathy and to examine the CAPN3 variants in Turkish and global populations.Materials and methods: Molecular analyses were performed using the next-generation sequencing (NGS) method. CAPN3 variants were identified through the examination of various databases.Results: In this retrospective study, the cohort consisted of seven patients exhibiting the CAPN3 (NM_000070.3) mutation and a phenotype compatible with calpainopathy at a single center in Türkiye. All patients displayed high CK levels and muscle weakness. We report a novel missense c.2437G>A variant that causes the autosomal dominant form of calpainopathy. Interestingly, the muscle biopsy report for the patient with the novel mutation indicated sarcoglycan deficiency. Molecular findings for the remaining individuals in the cohort included a compound heterozygous variant (frameshift and missense), one homozygous nonsense, one homozygous intronic deletion, and three homozygous missense variants. The most common variant in the Turkish population was c.550del. In both populations, pathogenic variants were most frequently located in exon 21, according to exon length. Variants were stochastically distributed based on consequences in CAPN3 domains.Conclusion: Therefore, the NGS method proves highly effective in diagnosing rare diseases characterized by clinical heterogeneity. Assessing variants based on ethnicity holds significance in the development of precise therapies.
- Open Access
- 14 September 2021
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 11 (6) , 675-682
COVID-19 vaccine candidates and vaccine development platforms available worldwide
- 14 September 2021
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 11 (6) , 675-682
Open AccessCOVID-19 vaccine candidates and vaccine development platforms available worldwide